A bacteria quietly living in your stomach
Most people have never heard of Helicobacter pylori — but roughly half the world's population carries this bacterium in their stomach. For many, it causes no obvious problems. For others, it silently erodes the stomach lining over years, leading to ulcers, chronic inflammation, and in some cases, a higher risk of stomach cancer.
Catching an active H. pylori infection is the first step to treating it — and treatment can significantly reduce that cancer risk.
The challenge with stomach damage
Here's where things get complicated. Some patients develop a condition called chronic atrophic gastritis (CAG) — a form of long-term stomach inflammation that permanently damages the glands that produce stomach acid. When those glands are damaged, the stomach becomes less acidic.
H. pylori actually thrives in higher-acid environments. So paradoxically, as the stomach lining deteriorates — and the very condition that raises cancer risk becomes more severe — the bacterium may become harder to detect. Tests that rely on markers of active H. pylori metabolism can give misleading results.
Old way vs. new possibility
Until recently, diagnosing active H. pylori infection in someone with CAG typically required an endoscopy — a procedure where a flexible camera is passed through the throat into the stomach to take tissue samples for analysis. That procedure is effective but invasive, uncomfortable, and not always accessible.
The monoclonal stool antigen test (SAT) offers a different path. It detects fragments of the H. pylori bacterium that are shed into the stool, using a highly specific antibody (a protein designed to lock onto one exact target). No scope, no sedation, no hospital visit required.
Think of the monoclonal antibody in this test like a very precise matching piece of a puzzle. It is engineered to fit only one specific fragment of the H. pylori bacterium. When that fragment is present in a stool sample, the antibody finds it and triggers a detectable signal. Because it is monoclonal — meaning derived from a single antibody type — it is far less likely to be triggered by unrelated material, which is why the specificity (the ability to avoid false positives) is high.
Who was studied
Researchers at a primary care center in China enrolled 287 patients who had been diagnosed with chronic atrophic gastritis. Each patient received the stool antigen test along with a urea breath test (another non-invasive H. pylori test) and a blood antibody test, and some also had tissue biopsies. Patients were divided into lower-risk and higher-risk groups based on the severity of their stomach lining damage and cancer progression risk.
The stool antigen test showed strong specificity — 96.1 percent — meaning it was extremely unlikely to say someone had H. pylori when they didn't. That's important for avoiding unnecessary treatment.
Sensitivity — the ability to correctly identify people who do have the infection — was 75.9 percent. That means roughly one in four infected patients tested negative on the stool test alone. That's a meaningful limitation.
Importantly, the test performed at least as well — and in some measures slightly better — in the high-risk group with more advanced stomach damage compared to the lower-risk group.
That last finding flips the expected logic: in the very patients where detection is considered hardest, this test held up best.
Expert context
The study authors position the stool antigen test not as a replacement for all diagnostic methods, but as a reliable first-line tool in primary care — especially useful for screening and for confirming eradication after antibiotic treatment. Its strong performance in high-risk patients is particularly noteworthy because those are the people for whom an accurate diagnosis matters most.
If you have been diagnosed with chronic gastritis and your doctor wants to check for H. pylori, a stool antigen test may be a reasonable, non-invasive option to discuss. It is already widely available in many countries. However, given the 76 percent sensitivity — meaning it can miss some infections — a negative result in a high-suspicion case may still warrant further testing, such as a breath test or endoscopy.
Limitations worth knowing
This study was conducted at a single center in China, which may limit how broadly the results apply. The sample of 287 patients is moderate in size. The test was also compared to a combined reference standard (breath test plus biopsy), which may not perfectly represent all real-world diagnostic scenarios.
Road ahead
Larger multi-center studies across diverse populations would help confirm whether the stool antigen test performs consistently in different health care settings. Researchers are also interested in whether combining multiple non-invasive tests — for example, the stool test and breath test together — could push sensitivity higher without sacrificing specificity.
